
The biotech industry flourishes with government support, driving economic growth through research investments and technological advancements. Moreover, the increased disease prevalence fuels demand for diagnostics and healthcare infrastructure, thereby propelling market expansion.
Therefore, investors could consider investing in top outsourcing stocks Gilead Sciences, Inc. (GILD), Incyte Corporation (INCY), Jazz Pharmaceuticals plc (JAZZ), and Exelixis, Inc. (EXEL) for 2024 gains.